#news #biotech Seattle Genetics stops all trials of ’33A blood cancer drug after patient deaths

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Seattle Genetics stops all trials of ’33A blood cancer drug after patient deaths .Seattle Genetics has called a halt to all clinical testing of vadastuximab talirine (SGN-CD33A) after seeing a higher rate of patient deaths with the drug in a phase 3 trial.

from FierceBiotech: Biotech http://ift.tt/2rw0wYY